Key facts
- This page summarizes Wright Don's Form 4 filing for International Stem Cell CORP (ISCO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 Jun 2021, 14:12.
Wright Don - 09 Jun 2021 Form 4 Insider Report for International Stem Cell CORP (ISCO)
- Reporting relationship
- Director
- Issuer ticker
- ISCO
- Reported as of
- 09 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Jun 2021, 14:12:08 UTC
- Next SEC filing
- 10 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sophia Garnette, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Wright Don filed Form 4 for International Stem Cell CORP (ISCO) on 11 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ISCO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +183,481
- Change %
- Price
- $0.000000
- Shares after
- 183,481
- Date
- 09 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 183,481
- Exercise price
- $0.3900
- Footnotes
- F1
ISCO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 09 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $0.3900
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Stock option granted as part of compensation for non-employee directors. Options vest in four equal quarterly increments, beginning 9/09/2021.
Footnote F2
Stock option granted as part of compensation for non-employee directors. Options vest fully at the earlier of (i) June 09, 2022 or (ii) the date of the 2022 Annual Meeting of Stockholders, with vesting accelerated for all shares in the event of a change in control.